SCHEMBL1897504

SCHEMBL1897504

CC(C)Cn1c(-c2nonc2N)nc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 6/20 1.00
GSK3B P49841 6/20 1.00
ROCK1 Q13464 5/20 1.00
PRKACA P17612 4/20 1.00
HTT P42858 5/20 0.78
TP53 P04637 3/20 0.78
POLB P06746 1/20 0.78
ATM Q13315 1/20 0.78
RPS6KA5 O75582 1/20 0.74
KDM4E B2RXH2 2/20 0.68
TSHR P16473 4/20 0.67
ALDH1A1 P00352 2/20 0.67
MAPT P10636 2/20 0.67
LMNA P02545 1/20 0.67
MAPK1 P28482 1/20 0.67
KCNK13 Q9HB14 1/20 0.63
MEN1 O00255 1/20 0.62
KMT2A Q03164 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1905525 0.88 HTT (1.00) RPS6KB1GSK3BROCK1PRKACAHTT
SCHEMBL1902125 0.87 RPS6KB1 (0.77) RPS6KB1GSK3BROCK1PRKACAHTT
SCHEMBL14364678 0.85 RPS6KB1 (0.74) RPS6KB1GSK3BROCK1PRKACAHTT
SCHEMBL14364584 0.85 RPS6KB1 (0.74) RPS6KB1GSK3BROCK1PRKACAHTT
Gw549034X SCHEMBL1900661 0.85 RPS6KA5 (1.00) RPS6KB1GSK3BROCK1PRKACAHTT
SCHEMBL14364651 0.84 PRKACA (0.72) RPS6KB1GSK3BROCK1PRKACAHTT
SCHEMBL1901013 0.83 HTT (1.00) RPS6KB1GSK3BROCK1PRKACAHTT
SCHEMBL14364661 0.83 RPS6KA5 (0.77) RPS6KB1GSK3BROCK1PRKACAHTT
SCHEMBL14364652 0.83 RPS6KB1 (0.70) RPS6KB1GSK3BROCK1PRKACAHTT
SCHEMBL12676576 0.82 KDM4E (0.80) RPS6KB1GSK3BROCK1PRKACAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322521-B1 Heteroaryl compounds useful as inhibitors of GSK-3 VERTEX PHARMA (US) 2013-09-04 EP claimed
EP-2322521-B1 Heteroaryl compounds useful as inhibitors of GSK-3 VERTEX PHARMA (US) 2013-09-04 EP disclosed
EP-2322521-A1 Heteroaryl compounds useful as inhibitors of GSK-3 Vertex Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed
EP-1472245-A2 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 Vertex Pharmaceuticals Incorporated (US) 2004-11-03 EP disclosed
US-20040034037-A1 Heteroaryl compounds useful as inhibitors of GSK-3 VERTEX PHARMACEUTICALS, INCORPORATED 2004-02-19 US disclosed
WO-2003066629-A2 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270420-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF GSK-3 GSK3B, GSK3A, GSKIP RPS6KB1 417/4885GSK3B 1/4885ROCK1 133/4885
US-20040034037-A1 Heteroaryl compounds useful as inhibitors of GSK-3 GSK3B, GSK3A, GSKIP RPS6KB1 417/4885GSK3B 1/4885ROCK1 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.